Early Commercial TractionSustained movement from near-zero to ~2.8M TTM revenue signals early commercial adoption and validates that the company can generate product receipts. This durable shift reduces binary clinical/R&D risk and provides a base to scale sales and improve operating leverage if growth continues.

Focused Product StrategyA single, well‑defined lead asset targeting oral mucositis (a common chemoradiotherapy complication) gives strategic clarity. Focused development can shorten go‑to‑market timelines, simplify regulatory and commercial planning, and make the program more attractive for partnerships or licensing.

Improving Cash Burn TrendA reduction in cash burn versus prior years indicates emerging operational discipline and progress toward stabilizing cash flows. Structurally, lower negative operating and free cash flow extends runway and gives management more time to execute commercialization or secure less dilutive financing.

Bears Say

Large Ongoing LossesMaterial and persistent operating losses are a structural constraint: they erode equity, produce negative returns on capital, and force continued external funding. Until profitability approaches, strategic options (R&D, marketing investments, partnerships) remain limited and dilution risk stays elevated.

Weak Cash GenerationConsistently negative operating and free cash flow (~-7.8M TTM) creates an ongoing reliance on external capital. This structural cash-generation weakness increases funding uncertainty, risks dilution or higher-cost debt, and constrains the company's ability to scale commercial and clinical activities sustainably.

Rising Leverage And Eroded EquityHigher debt and a sharply reduced equity cushion materially weaken financial flexibility. Increased leverage raises refinancing and covenant risks, elevates funding costs, and narrows the buffer against operating setbacks, making the firm more vulnerable to dilution or restrictive financing terms.

8LY FAQ

What was OncoZenge AB’s price range in the past 12 months?

OncoZenge AB lowest stock price was €0.34 and its highest was €0.67 in the past 12 months.

What is OncoZenge AB’s market cap?

OncoZenge AB’s market cap is €7.30M.

When is OncoZenge AB’s upcoming earnings report date?

OncoZenge AB’s upcoming earnings report date is May 19, 2026 which is in 79 days.

How were OncoZenge AB’s earnings last quarter?

OncoZenge AB released its earnings results on Feb 26, 2026. The company reported -€0.073 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.073.

Is OncoZenge AB overvalued?

According to Wall Street analysts OncoZenge AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does OncoZenge AB pay dividends?

OncoZenge AB does not currently pay dividends.

What is OncoZenge AB’s EPS estimate?

OncoZenge AB’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does OncoZenge AB have?

OncoZenge AB has 12,647,174 shares outstanding.

What happened to OncoZenge AB’s price movement after its last earnings report?

OncoZenge AB reported an EPS of -€0.073 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 1.344%.

Which hedge fund is a major shareholder of OncoZenge AB?

Currently, no hedge funds are holding shares in DE:8LY

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

OncoZenge AB

OncoZenge AB (publ), a pharmaceutical company, develops healthcare products for cancer supportive care. It offers BupiZenge, which has completed Phase 2 clinical trial for the treatment of oral mucositis. The company was founded in 2020 and is headquartered in Bromma, Sweden. OncoZenge AB (publ) is a subsidiary of Moberg Pharma AB (publ).